Company news
Tg Therapeutics, Inc. (NASDAQ:TGTX) news
Tg Therapeutics, Inc. news releases on 6ix. Latest, Mar 31, 2023: TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy)…
Press releases — page 3
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
March 30, 2023
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
March 2, 2023
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
February 27, 2023
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
February 23, 2023
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 23, 2023
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 13, 2023
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
January 25, 2023
TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 5, 2023
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
December 27, 2022
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 9, 2022
TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update
November 7, 2022
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
October 25, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
October 12, 2022
TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 8, 2022
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
August 24, 2022
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 7, 2022
TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business Update
August 4, 2022
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
June 26, 2022
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
June 2, 2022
TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS
May 30, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
May 25, 2022
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 19, 2022
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
April 25, 2022
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
April 14, 2022
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
April 5, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
April 3, 2022
TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
March 9, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
March 3, 2022
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL
March 2, 2022
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
February 28, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 24, 2022
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
February 23, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 14, 2022
TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference
January 23, 2022
TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million
January 3, 2022
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
December 13, 2021
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
December 13, 2021
TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting
December 12, 2021
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting
December 9, 2021
TG Therapeutics Provides Regulatory Update
November 29, 2021
TG Therapeutics to Participate in the Jefferies London Healthcare Conference
November 14, 2021
TG Therapeutics to Participate in the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series
November 8, 2021
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
November 3, 2021
TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
November 3, 2021
TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update
October 31, 2021
TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
October 13, 2021
TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
September 29, 2021
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
September 28, 2021
TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021